An enzymatic advance in nicotine cessation therapy
- PMID: 29308799
- PMCID: PMC6231713
- DOI: 10.1039/c7cc09134f
An enzymatic advance in nicotine cessation therapy
Abstract
A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.
Conflict of interest statement
Conflicts of interest
There are no conflicts to declare.
Figures
References
-
- World Health Organization., WHO Report on the Global Epidemic, 2013: Enforcing Bans on Tobacco Advertising, Promotion, Sponsorship, WHO Press, Geneva,Switzerland, 2013.
-
- Biener L, Reimer RL, Wakefield M, Szczypka G, Rigotti NA and Connolly G, Am. J. Prev. Med, 2006, 30, 217–224. - PubMed
-
- Xue S, Schlosburg JE and Janda KD, J. Am. Chem. Soc, 2015, 137, 10136–10139. - PubMed
-
- Janda KD and Treweek JB, Nat. Rev. Immunol, 2011, 12, 67–72. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
